Quelle

Literatura:
Corey KE., Vuppalanchi R., Wilson LA., et al.: “NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels.”, Aliment Pharmacol Ther., 2015.
Farnier M., Chen E., Johnsos-Levonas AO., et al.: “Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.”, Vasc Health Risk Manag., 2014.
Kuhnast S., van der Tuin SJ., van der Hoom W., van Klinken JB., et al.: “Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.”, Eur Heart J., 2015.
Liu A., Reaven GM.: “Is measurement of non-HDL cholesterol an effective way to identify the metabolic syndrome?”, Nutr Metab Cardiovasc Dis., 2013.
Poledne R., Kralova Lesna I., Kralova A., et al.: „The relationship between non-HDL cholesterol and macrophage phenotypes in human adipose tissue.”, J Lipid Res., 2016.
Ram N., Ahmed B., Hashmi F., Jabbar A.: “Importance of measuring non-HDL cholesterol in type 2 diabetes patients.”, J Pak Med Assoc., 2014.
Thanassoulis G., Williams K., Ye K., Brook R., Couture P., et al.: “Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials.”, J Am Heart Assoc., 2014.
Yu Y., Luo T., Liu S., Song G., et al.: “Chitosan Oligosaccharides Attenuate Atherosclerosis and Decrease Non-HDL in ApoE-/- Mice.”, J Atheroscler Thromb., 2015.